Members of the Premier hospital chain will have their choice of prostate brachytherapy products. Just one day after Mallinckrodt announced a deal to supply Premier members with UroCor’s ProstaSeed I-125 brachytherapy seed, the hospital chain signed a two-year contract with Nycomed Amersham Imaging for access to its brachytherapy technology.
Under terms of the agreement, all Premier members and affiliates will be eligible to purchase Princeton, NJ-based Nycomed’s OncoSeed and/or Rapid Strand I-125 brachytherapy products.
By AuntMinnie.com staff writers
August 3, 2000
Related Reading
Mallinckrodt to offer ProstaSeed, August 2, 2000
Syncor announces first I-125 seed user, July 26, 2000
Tyco announces deal to acquire Mallinckrodt, June 28, 2000
Nycomed spotlights OncoSeed study, May 4, 2000
Copyright © 2000 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
